Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reports that tofacitinib, a JAK inhibitor, may stabilize hair loss in patients with classic lichen planopilaris and frontal fibrosing alopecia, though hair regrowth was not robust.

This study observed that combining high-potency steroids with pimecrolimus might effectively stabilize hairline recession in frontal fibrosing alopecia patients.

Hair loss is a common but often unreported side effect of cancer treatments, especially for breast and prostate cancers.

This research developed new in vitro models for high-throughput screening of drugs that could protect or restore immune privilege in hair follicles, finding that Tofacitinib was effective in preventing inflammation-related marker upregulation, while Tacrolimus and αMSH worked specifically in outer root sheath keratinocytes.

This case study reported that a 24-year-old patient with severe, treatment-resistant alopecia areata experienced excellent clinical improvement after one month of treatment with tofacitinib, a JAK inhibitor.

This study found that topical application of the BRAF inhibitor vemurafenib improved wound healing and promoted hair follicle regeneration in a diabetic murine model.

This case study demonstrated that off-label tofacitinib treatment led to full regrowth of scalp hair after 18 months in a patient with alopecia areata universalis, following unsuccessful therapies.

Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.

This case report describes an adult Italian woman with endothrix tinea capitis, highlighting the unusual finding of telogen-sparing arthroconidia involvement during the infection.

Terbinafine 250 mg is the most effective treatment for fungal nail infections.

In this research letter from the British Journal of Dermatology, the authors explore the use of topical tofacitinib to treat alopecia areata affecting facial hair, but specific results are not reported in the abstract.

In this study, 40% of alopecia areata patients using topical 2% tofacitinib ointment achieved greater than 50% improvement in hair regrowth after six months, showing significant efficacy compared to controls, with no serious adverse effects reported.

In this case report, researchers observed that two sisters with congenital immune disorders experienced partial hair regrowth while receiving tofacitinib for severe alopecia areata, highlighting the need for careful clinical and laboratory monitoring due to potential infection risks associated with JAK inhibitor therapy.

This study found that Clitocybin A from Clitocybe aurantiaca significantly increased the proliferation of immortalized rat dermal papilla cells, suggesting potential hair growth-promoting effects in a laboratory setting.

In this case report, a 42-year-old woman with cutaneous dermatomyositis showed significant improvement, including reduction of erythema, pruritus, and scaling, after starting JAK inhibitor tofacitinib, especially when conventional systemic treatments failed and intravenous immune globulin wasn't viable.

In this case report, a young adult male with resistant alopecia areata showed nearly 90% hair regrowth after 3 months of treatment with tofacitinib, alongside biotin supplementation, without any side effects observed.

This study found that YiFa compound medicated serum significantly promoted the proliferation of follicle stem cells and increased mRNA expression of K19 and β1 integrin in a mouse model, suggesting a potential mechanism for treating alopecia.

This study found that targeting both hormonal and immune pathways improved treatment outcomes in androgenetic alopecia patients with an under-recognized inflammatory component called PIILIF, which may contribute to treatment resistance.

Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.

Clofazimine may be effective for treating ashy dermatosis.

This case report describes a successful treatment of alopecia universalis in a 37-year-old female using oral tofacitinib, along with other therapies, resulting in significant hair regrowth without notable safety concerns.

This review summarizes findings on the long-term use of tofacitinib for severe alopecia areata, reporting its potential as a promising treatment option.

This study found that olorofim demonstrated potent in vitro and in vivo antifungal activity against dermatophytes, resolving skin lesions in a guinea pig model similar to clotrimazole, suggesting it may be a promising treatment for dermatophytosis.

In this study, tofacitinib was reported to improve scalp hair regrowth in patients with severe alopecia areata, alopecia totalis, and alopecia universalis, showing a higher response in alopecia areata.

This study found that tofacitinib is an effective and more tolerable treatment than systemic corticosteroids for moderate-to-severe alopecia areata, and its combination with corticosteroids may offer improved efficacy.

In this case report, a patient with early-stage Frontal Fibrosing Alopecia showed substantial improvement in follicular density and inflammation control after three monthly sessions of Botulinum Toxin Type A administered via microinfusion.

This study found that both tofacitinib and methotrexate effectively reduced hair loss and psychological distress in patients with moderate-to-severe alopecia areata, but tofacitinib showed much greater efficacy. Both treatments had similar safety profiles, with no serious adverse effects reported.

This study found that prolonged tofacitinib treatment in adult Indian patients with moderate-to-severe alopecia areata was associated with a high regrowth rate, which varied with factors like age at disease onset and treatment duration.

This study found that Adapalene, Diosmin, and Azelastine have potential as multi-target drugs against Onchocerca volvulus and its endosymbiont, which might offer new therapeutic options for treating river blindness, but further research is needed to confirm their effectiveness.